Intravenous antioxidants, laetrile and artesunate as integrative treatment in oncology

Since 1970, Linus Pauling established that the C-Vitamin could potentially and selectively kill tumors by the induction of the hydrogen peroxide in the malignant cells, but not in the healthy cells. Increased levels of reactive oxygen species (ROS) including H 2 O 2 are thought to play an important role in the initiation and progression of cancer. Previous reports showed that vitamin C treatment induced cytotoxicity by adenosine triphosphate (ATP) depletion in some cancer cells. High-dose vitamin C suppressed tumor growth in animal models and tissue culture and, therefore, may indeed have applications as a novel treatment for various cancers. ALA, a member of the B vitamin family is a coenzyme in the multienzyme complexes of dehydrogenase and aminocaproic acid decarboxylase and can inhibit cancer cell proliferation in cervical cancer and colon cancer. Hydrogen cyanide is thought to be the main anticancer compound formed from laetrile via in situ release. Artemisinins have demonstrated cytotoxic effects against a variety of cancer cells by inducing cell cycle arrest, promoting apoptosis, preventing angiogenesis, and abrogating cancer invasion and metastasis. The aim is to show the integrative intravenous oncology protocols and the possible anticancer mechanisms behind.